Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Radiotherapy for pituitary adenomas: long-term outcome and complications

  • Rim, Chai-Hong (Department of Radiation Oncology, Korea University Medical Center) ;
  • Yang, Dae-Sik (Department of Radiation Oncology, Korea University Medical Center) ;
  • Park, Young-Je (Department of Radiation Oncology, Korea University Medical Center) ;
  • Yoon, Won-Sup (Department of Radiation Oncology, Korea University Medical Center) ;
  • Lee, Jung-Ae (Department of Radiation Oncology, Korea University Medical Center) ;
  • Kim, Chul-Yong (Department of Radiation Oncology, Korea University Medical Center)
  • Received : 2011.03.29
  • Accepted : 2011.06.08
  • Published : 2011.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate long-term local control rate and toxicity in patients treated with external beam radiotherapy (EBRT) for pituitary adenomas. Materials and Methods: We retrospectively reviewed the medical records of 60 patients treated with EBRT for pituitary adenoma at Korea University Medical Center from 1996 and 2006. Thirty-five patients had hormone secreting tumors, 25 patients had non-secreting tumors. Fifty-seven patients had received postoperative radiotherapy (RT), and 3 had received RT alone. Median total dose was 54 Gy (range, 36 to 61.2 Gy). The definition of tumor progression were as follows: evidence of tumor progression on computed tomography or magnetic resonance imaging, worsening of clinical sign requiring additional operation or others, rising serum hormone level against a previously stable or falling value, and failure of controlling serum hormone level so that the hormone level had been far from optimal range until last follow-up. Age, sex, hormone secretion, tumor extension, tumor size, and radiation dose were analyzed for prognostic significance in tumor control. Results: Median follow-up was 5.7 years (range, 2 to 14.4 years). The 10-year actuarial local control rates for non-secreting and secreting adenomas were 96% and 66%, respectively. In univariate analysis, hormone secretion was significant prognostic factor (p = 0.042) and cavernous sinus extension was marginally significant factor (p = 0.054) for adverse local control. All other factors were not significant. In multivariate analysis, hormone secretion and gender were significant. Fifty-three patients had mass-effect symptoms (headache, dizziness, visual disturbance, hypopituitarism, loss of consciousness, and cranial nerve palsy). A total of 17 of 23 patients with headache and 27 of 34 patients with visual impairment were improved. Twenty-seven patients experienced symptoms of endocrine hypersecretion (galactorrhea, amenorrhea, irregular menstruation, decreased libido, gynecomastia, acromegaly, and Cushing's disease). Amenorrhea was abated in 7 of 10 patients, galactorrhea in 8 of 8 patients, acromegaly in 7 of 11 patients, Cushing's disease in 4 of 4 patients. Long-term complication was observed in 4 patients; 3 patients with cerebrovascular accident, 1 patient developed dementia. Of these patients, 3 of 4 received more than 60 Gy of irradiation. Conclusion: EBRT is highly effective in preventing recurrence and reducing mass effect of non-secreting adenoma. Effort to improve tumor control of secreting adenoma is required. Careful long-term follow-up is required when relatively high dose is applied. Modern radiosurgery or proton RT may be options to decrease late complications.

Keywords

References

  1. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999;1:14-25.
  2. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;120:817-20. https://doi.org/10.7326/0003-4819-120-10-199405150-00001
  3. Muhr C, Bergstrom K, Grimelius L, Larsson SG. A parallel study of the roentgen anatomy of the sella turcica and the histopathology of the pituitary gland in 205 autopsy specimens. Neuroradiology 1981;21:55-65. https://doi.org/10.1007/BF00342982
  4. Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation: a follow-up study. Clin Endocrinol (Oxf) 1999;51:281-4. https://doi.org/10.1046/j.1365-2265.1999.00865.x
  5. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-8. https://doi.org/10.1111/j.1365-2265.1993.tb02137.x
  6. Grigsby PW, Stokes S, Marks JE, Simpson JR. Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 1988;15:1103-10. https://doi.org/10.1016/0360-3016(88)90191-5
  7. Snead FE, Amdur RJ, Morris CG, Mendenhall WM. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 2008;71:994-8. https://doi.org/10.1016/j.ijrobp.2007.11.057
  8. Roberge D, Shenouda G, Souhami L. Pituitary. In: Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 751-64.
  9. Lee JY, Park KR, Kim HJ, Lee CI, Kim MS, Jung SH. Glioblastoma after radiotherapy for pituitary adenoma. J Korean Soc Ther Radiol Oncol 1999;17:287-92.
  10. Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term effi cacy and toxicity. Radiother Oncol 2009;93:597-601. https://doi.org/10.1016/j.radonc.2009.09.011
  11. Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys 2000;47:1337-45. https://doi.org/10.1016/S0360-3016(00)00503-4
  12. Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 1996;41:45-53. https://doi.org/10.1016/S0167-8140(96)91807-1
  13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81. https://doi.org/10.1080/01621459.1958.10501452
  14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
  15. Popovic EA, Vattuone JR, Siu KH, Busmanis I, Pullar MJ, Dowling J. Malignant prolactinomas. Neurosurgery 1991;29:127-30. https://doi.org/10.1227/00006123-199107000-00023
  16. Ciric I, Mikhael M, Stafford T, Lawson L, Garces R. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J Neurosurg 1983;59:395-401. https://doi.org/10.3171/jns.1983.59.3.0395
  17. Gittoes NJ, Bates AS, Tse W, et al. Radiotherapy for nonfunction pituitary tumours. Clin Endocrinol (Oxf) 1998;48:331-7. https://doi.org/10.1046/j.1365-2265.1998.00393.x
  18. Greenman Y, Ouaknine G, Veshchev I, Reider G II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 2003;58:763-9. https://doi.org/10.1046/j.1365-2265.2003.01784.x
  19. Hughes MN, Llamas KJ, Yelland ME, Tripcony LB. Pituitary adenomas: long-term results for radiotherapy alone and post-operative radiotherapy. Int J Radiat Oncol Biol Phys 1993;27:1035-43. https://doi.org/10.1016/0360-3016(93)90520-6
  20. McCord MW, Buatti JM, Fennell EM, et al. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997;39:437-44. https://doi.org/10.1016/S0360-3016(97)00335-0
  21. Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 2005;62:333-41. https://doi.org/10.1016/j.ijrobp.2004.09.058
  22. Brada M, Burchell L, Ashley S, Traish D. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999;45:693-8. https://doi.org/10.1016/S0360-3016(99)00159-5
  23. Ono Y, Maehara F. Complication of irradiation in brain tumors. Gan No Rinsho 1989;35:1347-53.
  24. Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010;174:865-9. https://doi.org/10.1667/RR1862.1
  25. Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008;62:1262-9. https://doi.org/10.1227/01.neu.0000333297.41813.3d
  26. Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly: long-term experience. Clin Endocrinol (Oxf) 2006;64:588-95. https://doi.org/10.1111/j.1365-2265.2006.02513.x
  27. Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2008;93:2546-52. https://doi.org/10.1210/jc.2008-0135
  28. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007;13:726-34. https://doi.org/10.4158/EP.13.7.726
  29. Aghi MK, Petit J, Chapman P, et al. Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 2008;55:141-4.
  30. Rush S, Cooper PR. Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Int J Radiat Oncol Biol Phy 1997;37:1031-4. https://doi.org/10.1016/S0360-3016(96)00586-X
  31. Dekkers OM, van der Klaauw AA, Pereira AM, et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006;91:3364-9. https://doi.org/10.1210/jc.2006-0003

Cited by

  1. Characteristics of Acromegaly in Korea with a Literature Review vol.28, pp.3, 2011, https://doi.org/10.3803/enm.2013.28.3.164
  2. Excess Mortality Associated With Hypopituitarism in Adults: A Meta-Analysis of Observational Studies vol.100, pp.4, 2011, https://doi.org/10.1210/jc.2014-3787
  3. Effective time window in reducing pituitary adenoma size by gamma knife radiosurgery vol.18, pp.4, 2015, https://doi.org/10.1007/s11102-014-0603-8
  4. Long-term Outcome After Fractionated Radiotherapy for Pituitary Adenoma: The Curse of the Secretory Tumor vol.39, pp.1, 2011, https://doi.org/10.1097/coc.0000000000000014
  5. Long-term outcomes of surgery and radiotherapy for secreting and non-secreting pituitary adenoma vol.34, pp.2, 2011, https://doi.org/10.3857/roj.2016.01683
  6. Fractionated Stereotactic Radiotherapy for Pituitary Adenomas vol.79, pp.3, 2011, https://doi.org/10.1227/neu.0000000000001155
  7. Management of nonfunctioning pituitary tumors: radiotherapy vol.21, pp.2, 2018, https://doi.org/10.1007/s11102-018-0868-4
  8. Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes vol.8, pp.None, 2011, https://doi.org/10.3389/fonc.2018.00660
  9. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options vol.20, pp.10, 2011, https://doi.org/10.1007/s12094-018-1868-6
  10. Radiomics Approach for Prediction of Recurrence in Non-Functioning Pituitary Macroadenomas vol.10, pp.None, 2011, https://doi.org/10.3389/fonc.2020.590083
  11. Current perspectives on recurrent pituitary adenoma: The role and timing of surgery vs adjuvant treatment vol.92, pp.2, 2011, https://doi.org/10.1111/cen.14127
  12. Prediction of recurrence in solid nonfunctioning pituitary macroadenomas: additional benefits of diffusion-weighted MR imaging vol.132, pp.2, 2011, https://doi.org/10.3171/2018.10.jns181783